9 results about "FOXP3" patented technology

A method for determining whether a subject is at risk for having a progressing or high-grade pre-invasive lesion, nodule or small mass, or having a solid malignant tumour is described the method comprising: (i) determining a ratio of activated and / or exhausted T cells:naive and / or resting T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, or (ii) determining a ratio of activated and / or exhausted T cells:T cells which are not activated and / or exhausted T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, (iii) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising Ki67 and CD39, and / or (iv) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the T cells are CD4 T cells, and wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising FoxP3.

The present application relates to the medical technical field, especially to the application of FYB1 gene as a marker in preparation of gastric cancer diagnosis or prognosis judging reagent. The present application research finds that FYB1 gene is highly expressed in gastric cancer tissue and negatively correlated with the prognosis of patients, and can be used as a gastric cancer marker for gastric cancer detection and efficacy evaluation. In addition, FYB1 is positively correlated with the expression of Treg cell marker FOXP3 and co-localized in tissues, suggesting that FYB1 may promote gastric cancer tumor immune escape; the expression of FYB1 gene can significantly inhibit the proliferation, migration and invasion ability of gastric cancer cells, and inhibit tumor growth, indicating that FYB1 gene can be used as a gastric cancer treatment target and play an important role in the treatment of gastric cancer patients.

This application discloses an IL-2 variant fusion protein and its applications. The IL-2 variant fusion protein of this application comprises 1) wild-type hIL-2 or an hIL-2 mutant protein, 2) an hIgG1-HC-Fc mutant fragment, and 3) an hIgG1-LC fragment; the hIL-2 mutant protein is obtained by an N88D mutation in wild-type hIL-2; the hIgG1-HC-Fc mutant fragment is obtained by L236A, L237A, and P331G mutations in wild-type hIgG1-HC-Fc. This IL-2 variant fusion protein, as a novel drug, can regulate Tregs (Foxp3). + ), treatment for Tregs (Foxp3) + This is associated with various refractory autoimmune diseases and inflammation, and prolongs the duration of Tregs (Foxp3). + Related health and lifespan span.

Compositions and methods are described herein that are useful for the detection of prostate cancer progression by determining the expression levels of genes associated with metastatic PCa. Based on the expression of IL-6, SELE, FOSB, NRK, NFRB2, FOXP3, ARG1, CEBPDP, TNFα, ADAMTS4, PENK, FOSL1, DUSP1, ACTA1, AGT, ATF3, CDK1, CXCL8, SELP, VCAN, TFP12, or NR4A3 genes or any combination thereof, treatment of PCa with SELE agonists, TNFα antagonists, and / or immune checkpoint inhibitors (ICIs) are shown to be effective.

The present invention relates to universal immunomodulatory T cells comprising a chimeric antigen receptor and uses thereof and, specifically, to universal immunomodulatory T cells in which immunogenicity of cells is removed so that general T cells obtainable in sufficient numbers from healthy people can be applied to all organ transplant patients and in which Foxp3 and a chimeric antigen receptor are both introduced, and a use thereof.

An expression construct, a nucleic acid or vector or cell comprising said expression construct, and various uses of said expression construct, nucleic acid, vector or cell is disclosed herein. Particularly, an expression construct comprising a PGK promoter operably linked to (i) a first nucleotide sequence encoding a chimeric antigen receptor (CAR), and (ii) a second nucleotide sequence encoding a FOXP3 polypeptide, wherein the first nucleotide sequence is located upstream of the second nucleotide sequence, is provided.

A method for generating immuno-free and stress-resistant donor cells comprising editing PRDM1 and FOXP3 genes in T-cells and B-cells with CRISPR-Cas9 and modulating immune responses to reduce inflammation and prevent autoimmunity. Particularly, the present invention discloses a method for treating Type 1 Diabetes, comprising genetically modifying pancreatic beta cells with CRISPR-Cas9, and altering HLA expression, and upregulating immune checkpoint molecules such as PD-L1 to obtain immune-tolerant and stress-resistant pancreatic beta cells.

This invention discloses a novel CD8 + T cells and CD4 + T cell subsets. The CD8... + T cell subsets include: subsets characteristically expressing GZMK and PDCD1; subsets characteristically expressing GZMK, GPR183, IL7R, and ZNF683; subsets characteristically expressing GZMK and CXCL13; subsets characteristically expressing GZMK and ZNF683; and subsets expressing at least one of the following KIR genes: KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2, and KIR3DL3. The CD4+... + T cell subsets include: subsets that characteristically express FOXP3, TNFRSF9, and CTLA4; and subsets that characteristically express FOXP3 and BACH1.